nach oben

NeuroMolecular Medicine

Erschienen in:

01.12.2014 | Original Paper

Epigenome-Wide Association Study for Parkinson’s Disease

verfasst von: Kerry Moore, Amy Jayne McKnight, David Craig, Francis O’Neill

Erschienen in: NeuroMolecular Medicine | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

A methylation-based EWAS on carefully phenotyped individuals with Parkinson’s disease (PD) was conducted to reveal prioritised genes and pathways with statistically significant and sizable changes in PD and in the anxiety that often accompanies it. This was followed by subsequent replication of top-ranked CpG sites. Using the Infinium^® HumanMethylation 450K beadchip (Illumina Inc., USA), twenty unique genes with a sizable difference in methylation (P _adjusted < 0.05, Δβ ≥ 0.2), after correction for multiple testing, were identified between PD and controls, while seventeen were identified between PD with anxiety and PD without anxiety. Twelve top ranked, significantly associated loci in PD were evaluated in an independent replicate population using Sequenom EpiTYPER for 219 individuals with similar phenotypes to the cross-sectional case–control discovery design. FANCC cg14115740 and TNKS2 cg11963436 show significant differential methylation between PD cases and controls using both techniques and their Δβ values, which have the same direction of effect, are reasonable to warrant further investigation.

Nur mit Berechtigung zugänglich

Almeida Mdo, R. (2012). Glucocerebrosidase involvement in Parkinson disease and other synucleinopathies. Frontiers in Neurology, 3, 65.PubMed

Ardley, H. C., Scott, G. B., Rose, S. A., Tan, N. G., & Robinson, P. A. (2004). UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson’s disease. Journal of Neurochemistry, 90(2), 379–391.PubMedCrossRef

Bajaj, A., Driver, J. A., & Schernhammer, E. S. (2010). Parkinson’s disease and cancer risk: A systematic review and meta-analysis. Cancer Causes & Control: CCC, 21(5), 697–707.PubMedCrossRef

Bando, Y., Onuki, R., Katayama, T., Manabe, T., Kudo, T., Taira, K., et al. (2005). Double-strand RNA dependent protein kinase (PKR) is involved in the extrastriatal degeneration in Parkinson’s disease and Huntington’s disease. Neurochemistry International, 46(1), 11–18.PubMedCrossRef

Bell, C. G., Teschendorff, A. E., Rakyan, V. K., Maxwell, A. P., Beck, S., & Savage, D. A. (2010). Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Medical Genomics, 3, 33.PubMedCentralPubMedCrossRef

Benjamini, Y., & H, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B, 57(1), 289–300.

Ben-Shlomo, Y. (1996). How far are we in understanding the cause of Parkinson’s disease? Journal of Neurology, Neurosurgery and Psychiatry, 61(1), 4–16.PubMedCentralPubMedCrossRef

Breitling, L. P., Yang, R., Korn, B., Burwinkel, B., & Brenner, H. (2011). Tobacco-smoking-related differential DNA methylation: 27 K discovery and replication. American Journal of Human Genetics, 88(4), 450–457.PubMedCentralPubMedCrossRef

Chan, N. C., & Chan, D. C. (2011). Parkin uses the UPS to ship off dysfunctional mitochondria. Autophagy, 7(7), 771–772.PubMedCentralPubMedCrossRef

Chowdhury, S., Erickson, S. W., Macleod, S. L., Cleves, M. A., Hu, P., Karim, M. A., et al. (2011). Maternal genome-wide DNA methylation patterns and congenital heart defects. PLoS one, 6(1), e16506.PubMedCentralPubMedCrossRef

Clarke, C. E. (Ed.). (2007). Parkinson’s Disease (2nd ed.). London: Royal Society of Medicine Press Ltd.

Cook, C., Stetler, C., & Petrucelli, L. (2012). Disruption of protein quality control in Parkinson’s disease. Cold Spring Harbor Perspectives in Medicine, 2(5), a009423.PubMedCentralPubMedCrossRef

Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994). The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology, 44(12), 2308–2314.PubMedCrossRef

Dahl, C., & Guldberg, P. (2003). DNA methylation analysis techniques. Biogerontology, 4(4), 233–250.PubMedCrossRef

Daniel, S. E., & Lees, A. J. (1993). Parkinson’s Disease Society Brain Bank, London: Overview and research. Journal of Neural Transmission. Supplementum, 39, 165–172.PubMed

Dehay, B., Martinez-Vicente, M., Ramirez, A., Perier, C., Klein, C., Vila, M., et al. (2012). Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove. Autophagy, 8(9), 1389–1391.PubMedCentralPubMedCrossRef

Desideri, E., & Martins, L.M. (2012). Mitochondrial stress signalling: HTRA2 and Parkinson’s disease. International Journal of Cell Biology, 2012, 607929.

Flintoft, L. (2011). Disease epigenomics: A smoking gun. Nature Reviews Genetics, 12(5), 300.PubMedCrossRef

Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189–198.PubMedCrossRef

Grupe, A., Li, Y., Rowland, C., Nowotny, P., Hinrichs, A. L., Smemo, S., et al. (2006). A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. American Journal of Human Genetics, 78(1), 78–88.PubMedCentralPubMedCrossRef

Hancock, D. B., Martin, E. R., Mayhew, G. M., Stajich, J. M., Jewett, R., Stacy, M. A., et al. (2008). Pesticide exposure and risk of Parkinson’s disease: A family-based case-control study. BMC Neurology, 8, 6.PubMedCentralPubMedCrossRef

Handel, A. E., Ebers, G. C., & Ramagopalan, S. V. (2010). Epigenetics: Molecular mechanisms and implications for disease. Trends in Molecular Medicine, 16(1), 7–16.PubMedCrossRef

Harris, R. A., Nagy-Szakal, D., Pedersen, N., Opekun, A., Bronsky, J., Munkholm, P., et al. (2012). Genome-wide peripheral blood leukocyte DNA methylation microarrays identified a single association with inflammatory bowel diseases. Inflammatory Bowel Diseases, 18(12), 2334–2341.PubMedCrossRef

Illumina, 09/03/12, 2012-last update, Infinium HumanMethylation450 BeadChip. [Homepage of Illumina] [Online]. Available: http://www.illumina.com/documents/products/datasheets/datasheet_humanmethylation450.pdf [03/20, 2012].

International Parkinson’s Disease Genomics Consortium (IPDGC) And Wellcome Trust Case Control Consortium 2 (WTCCC2). (2011). A two-stage meta-analysis identifies several new loci for Parkinson’s disease. PLoS Genetics, 7(6), e1002142.CrossRef

Jellinger, K. (1988). The pedunculopontine nucleus in Parkinson’s disease, progressive supranuclear palsy and Alzheimer’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 51(4), 540–543.PubMedCentralPubMedCrossRef

Jellinger, K. A. (2009). Formation and development of Lewy pathology: A critical update. Journal of Neurology, 256(Suppl 3), 270–279.PubMedCrossRef

Johnson, M. R., Lydiard, R. B., Zealberg, J. J., Fossey, M. D., & Ballenger, J. C. (1994). Plasma and CSF HVA levels in panic patients with comorbid social phobia. Biological Psychiatry, 36(6), 425–427.PubMedCrossRef

Jowaed, A., Schmitt, I., Kaut, O., & Wullner, U. (2010). Methylation regulates alpha-synuclein expression and is decreased in Parkinson’s disease patients’ brains. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 30(18), 6355–6359.CrossRef

Junn, E., Taniguchi, H., Jeong, B. S., Zhao, X., Ichijo, H., & Mouradian, M. M. (2005). Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proceedings of the National Academy of Sciences of the United States of America, 102(27), 9691–9696.PubMedCentralPubMedCrossRef

Kaminker, P. G., Kim, S. H., Taylor, R. D., Zebarjadian, Y., Funk, W. D., Morin, G. B., et al. (2001). TANK2, a new TRF1-associated poly(ADP-ribose) polymerase, causes rapid induction of cell death upon overexpression. The Journal of Biological Chemistry, 276(38), 35891–35899.PubMedCrossRef

Kummer, A., Cardoso, F., & Teixeira, A. L. (2008). Frequency of social phobia and psychometric properties of the Liebowitz social anxiety scale in Parkinson’s disease. Movement Disorders: Official Journal of the Movement Disorder Society, 23(12), 1739–1743.CrossRef

Kummer, A., & Teixeira, A. L. (2009). Neuropsychiatry of Parkinson’s disease. Arquivos de Neuro-Psiquiatria, 67(3B), 930–939.PubMedCrossRef

Lang, A. E. T., & Fahn, S. (1989). Assessment of Parkinson’s disease. In T. L. Munsat (Ed.), Quantification of neurological deficit (pp. 285–309). Boston: Butterworths.

Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983). Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (New York), 219(4587), 979–980.CrossRef

Lill, C. M., Roehr, J. T., McQueen, M. B., Kavvoura, F. K., Bagade, S., Schjeide, B. M., et al. (2012). Comprehensive research synopsis and systematic meta-analyses in Parkinson’s disease genetics: The PDGene database. PLoS Genetics, 8(3), e1002548.PubMedCentralPubMedCrossRef

Liu, B., Gao, H. M., & Hong, J. S. (2003). Parkinson’s disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: Role of neuroinflammation. Environmental Health Perspectives, 111(8), 1065–1073.PubMedCentralPubMedCrossRef

Liu, H., Liu, W., Wu, Y., Zhou, Y., Xue, R., Luo, C., et al. (2005). Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Research, 65(17), 7635–7643.PubMed

Mailman, M. D., Feolo, M., Jin, Y., Kimura, M., Tryka, K., Bagoutdinov, R., et al. (2007). The NCBI dbGaP database of genotypes and phenotypes. Nature Genetics, 39(10), 1181–1186.PubMedCentralPubMedCrossRef

Marques, S. C., Oliveira, C. R., Pereira, C. M., & Outeiro, T. F. (2011). Epigenetics in neurodegeneration: A new layer of complexity. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(2), 348–355.PubMedCrossRef

Marsit, C. J., Koestler, D. C., Christensen, B. C., Karagas, M. R., Houseman, E. A., & Kelsey, K. T. (2011). DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer. Journal of clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29(9), 1133–1139.CrossRef

Muzerengi, S., Contrafatto, D., & Chaudhuri, K. R. (2007). Non-motor symptoms: Identification and management. Parkinsonism and Related Disorders, 13(Suppl 3), 450–456.CrossRef

Nutt, D. J., Bell, C. J., & Malizia, A. L. (1998). Brain mechanisms of social anxiety disorder. The Journal of Clinical Psychiatry, 59(Suppl 17), 4–11.PubMed

Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science (New York), 276(5321), 2045–2047.CrossRef

Pontone, G. M., Williams, J. R., Anderson, K. E., Chase, G., Goldstein, S. A., Grill, S., et al. (2009). Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson’s disease. Movement Disorders: Official Journal of the Movement Disorder Society, 24(9), 1333–1338.CrossRef

Qureshi, I. A., & Mehler, M. F. (2011). Advances in epigenetics and epigenomics for neurodegenerative diseases. Current Neurology and Neuroscience Reports, 11(5), 464–473.PubMedCrossRef

Rakyan, V. K., Down, T. A., Balding, D. J., & Beck, S. (2011). Epigenome-wide association studies for common human diseases. Nature Reviews Genetics, 12(8), 529–541.PubMedCentralPubMedCrossRef

Ren, H., Fu, K., Wang, D., Mu, C., & Wang, G. (2011). Oxidized DJ-1 interacts with the mitochondrial protein BCL-XL. The Journal of Biological Chemistry, 286(40), 35308–35317.PubMedCentralPubMedCrossRef

Robinson, H. M., Hood, S. D., Bell, C. J., & Nutt, D. J. (2006). Dopamine and social anxiety disorder. Revista brasileira de psiquiatria (Sao Paulo, Brazil: 1999), 28(4), 263–264.CrossRef

Schneier, F. R., Liebowitz, M. R., Abi-Dargham, A., Zea-Ponce, Y., Lin, S. H., & Laruelle, M. (2000). Low dopamine D(2) receptor binding potential in social phobia. The American Journal of Psychiatry, 157(3), 457–459.PubMedCrossRef

Schrag, A. (2006). Quality of life and depression in Parkinson’s disease. Journal of the Neurological Sciences, 248(1–2), 151–157.PubMedCrossRef

Siemers, E. R., Shekhar, A., Quaid, K., & Dickson, H. (1993). Anxiety and motor performance in Parkinson’s disease. Movement Disorders: Official Journal of the Movement Disorder Society, 8(4), 501–506.CrossRef

Smyth, L. J., McKay, G. J., Maxwell, A. P., & McKnight, A. J. (2014). DNA hypermethylation and DNA hypomethylation is present at different loci in chronic kidney disease. Epigenetics: Official Journal of the DNA Methylation Society, 9(3), 366–376.CrossRef

Stern, M., Dulaney, E., Gruber, S. B., Golbe, L., Bergen, M., Hurtig, H., et al. (1991). The epidemiology of Parkinson’s disease: A case-control study of young-onset and old-onset patients. Archives of Neurology, 48(9), 903–907.PubMedCrossRef

Sun, F., Kanthasamy, A., Anantharam, V., & Kanthasamy, A. G. (2007). Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson’s disease. Pharmacology & Therapeutics, 114(3), 327–344.CrossRef

Wilhelmus, M. M., Nijland, P. G., Drukarch, B., de Vries, H. E., & van Horssen, J. (2012). Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders. Free Radical Biology & Medicine, 53(4), 983–992.CrossRef

Wing, M. R., Devaney, J. M., Joffe, M. M., Xie, D., Feldman, H. I., Dominic, E. A., et al. (2014). DNA methylation profile associated with rapid decline in kidney function: Findings from the CRIC study. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association—European Renal Association, 29(4), 864–872.CrossRef

Zhu, Y., Stevens, R. G., Hoffman, A. E., Tjonneland, A., Vogel, U. B., Zheng, T., et al. (2011). Epigenetic impact of long-term shiftwork: Pilot evidence from circadian genes and whole-genome methylation analysis. Chronobiology International, 28(10), 852–861.PubMedCentralPubMedCrossRef

Titel: Epigenome-Wide Association Study for Parkinson’s Disease
verfasst von: Kerry Moore
Amy Jayne McKnight
David Craig
Francis O’Neill
Publikationsdatum: 01.12.2014
Verlag: Springer US
Erschienen in: NeuroMolecular Medicine / Ausgabe 4/2014
Print ISSN: 1535-1084
Elektronische ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-014-8332-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Epigenome-Wide Association Study for Parkinson’s Disease

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Neurologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Oculopharyngeal Muscular Dystrophy: Phenotypic and Genotypic Studies in a Chinese Population

A Polymorphism in the Promoter Region of the Survivin Gene is Related to Hemorrhagic Transformation in Patients with Acute Ischemic Stroke

Mitochondrial Oxidative Phosphorylation Transcriptome Alterations in Human Amyotrophic Lateral Sclerosis Spinal Cord and Blood

Apolipoprotein E Isoform-Specific Effects on Lipoprotein Receptor Processing

Inhibitors of Histone Deacetylases Enhance Neurotoxicity of DNA Damage

Propofol Protects Against Angiotensin II-Induced Mouse Hippocampal HT22 Cells Apoptosis Via Inhibition of p66Shc Mitochondrial Translocation

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Neurologie